RESEARCH ATLASRESEARCH > HYPE
PUBLIC RESEARCH EDITION
Appetite / ghrelin

LEAP2

Ghrelin receptor (GHSR) endogenous antagonist and inverse agonist · Peptide
Also known as LEAP-2, Liver-expressed antimicrobial peptide 2

Evidence at a glance

Each record keeps its own evidence class. Counts are records in this public edition, not a quality score.

Open in the interactive library →Compare with other compounds →

Records (1)

U

Unresolved / evidence gap

Unresolved / evidence gap

LEAP2 review: endogenous ghrelin-receptor antagonist in obesity (2021)

A 2021 review describes LEAP2 as an endogenous competitive antagonist and inverse agonist of the ghrelin receptor (GHS-R1a). Plasma LEAP2 rises with feeding and obesity and falls with fasting and weight loss, the opposite of ghrelin.

Context: Narrative review of human and animal studies.

Limitations: Review with no new data.

Route: Not documented

Open this exact record in the library →Suggest a correction
CONTINUE THE RESEARCH

Follow the pathway.

No other compound in this public edition uses this pathway label.

Browse this pathway in the library →

Educational research summary. Study amounts are research context, not a dose recommendation. Not medical advice.